We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| BioNTech SE | NASDAQ:BNTX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.15 | 1.25% | 93.39 | 92.02 | 93.40 | 93.54 | 91.60 | 93.42 | 663,328 | 01:00:00 |
From Nov 2023 to May 2024
13:51 EST -- Covid vaccine maker BioNTech is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. BioNTech reported a surprise third-quarter profit and better-than-expected sales, leading its stock to surge. But BioNTech cut its 2023 guidance, expecting 4 billion euros in sales of the Pfizer-partnered Covid shot, about $4.29 billion, down from previous guidance for EUR5 billion. BioNTech noted fewer people are getting primary vaccinations and population-wide boosting is much lower. BioNTech is now focusing on areas outside its Covid vaccine. "Our strategy focuses on assembling a diverse toolbox of complementary technologies to deliver novel therapies, aiming to improve the standard-of-care for cancer patients," Chief Executive Ugur Sahin said. Dow Jones & Co. owns Factiva. (matthew.walker@dowjones.com)
(END) Dow Jones Newswires
November 06, 2023 14:07 ET (19:07 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year BioNTech Chart |
1 Month BioNTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
